Subependymal giant cell astrocytoma medical therapy: Difference between revisions
Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
The predominant therapy for subependymal giant cell astrocytoma is surgical resection. Adjunctive chemotherapy may be required.<ref name="pmid21465222">{{cite journal| author=Campen CJ, Porter BE| title=Subependymal Giant Cell Astrocytoma (SEGA) Treatment Update. | journal=Curr Treat Options Neurol | year= 2011 | volume= 13 | issue= 4 | pages= 380-5 | pmid=21465222 | doi=10.1007/s11940-011-0123-z | pmc=PMC3130084 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21465222 }} </ref> | |||
==Medical Therapy== | ==Medical Therapy== |
Revision as of 19:00, 5 November 2015
Subependymal giant cell astrocytoma Microchapters |
Differentiating Subependymal Giant Cell Astrocytoma from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Subependymal giant cell astrocytoma medical therapy On the Web |
American Roentgen Ray Society Images of Subependymal giant cell astrocytoma medical therapy |
Subependymal giant cell astrocytoma medical therapy in the news |
Blogs on Subependymal giant cell astrocytoma medical therapy |
Risk calculators and risk factors for Subependymal giant cell astrocytoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
The predominant therapy for subependymal giant cell astrocytoma is surgical resection. Adjunctive chemotherapy may be required.[1]
Medical Therapy
The treatment options for subependymal giant cell astrocytoma include the following:[2][1]
Treatment of subependymal giant cell astrocytoma | |||||||||||||||||||||||||||||||||||||||||
Surgery | Gamma knife radiosurgery | Chemotherapy | |||||||||||||||||||||||||||||||||||||||
Rapamycin | Everolimus | ||||||||||||||||||||||||||||||||||||||||
Chemotherapy
Reference
- ↑ 1.0 1.1 Campen CJ, Porter BE (2011). "Subependymal Giant Cell Astrocytoma (SEGA) Treatment Update". Curr Treat Options Neurol. 13 (4): 380–5. doi:10.1007/s11940-011-0123-z. PMC 3130084. PMID 21465222.
- ↑ Jóźwiak S, Nabbout R, Curatolo P, participants of the TSC Consensus Meeting for SEGA and Epilepsy Management (2013). "Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Clinical recommendations". Eur J Paediatr Neurol. 17 (4): 348–52. doi:10.1016/j.ejpn.2012.12.008. PMID 23391693.